Alcresta : US FDA clears expanded use of Alcresta Therapeutics' RELiZORB cartridge for paediatric patients ages 2 to 5 years

Alcresta Therapeutics, Inc., a leading commercial─stage company focused on developing and commercializing novel enzyme─based products, announced that the US Food and Drug Administration (FDA) has cleared